JPX:4577
Daito Pharmaceutical Co.,Ltd. · JPX · Healthcare · JPY · FY for 2026
Figures on this page computed 2026-11-08 13:45 UTC
Last close
n/aJPY
Market data
12.1xP/E
Price / Earnings per Share (diluted)
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- JPY
- computed
- Computed from the filing for 2026
4.6%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- JPY
- Computed from the filing for 2026
- Computed from the filing for 2026
- Computed from the filing for 2026
- Computed from the filing for 2026
- Computed from the filing for 2026
- Computed from the filing for 2026
6.2%Net margin
Net Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- JPY
- Computed from the filing for 2026
- Computed from the filing for 2026
10.9%FCF margin
Free Cash Flow / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- JPY
- Computed from the filing for 2026
- Computed from the filing for 2026
0.18Debt/equity
Total Debt / Shareholders' Equity
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- JPY
- Computed from the filing for 2026
- Computed from the filing for 2026
2.9%Dividend yield
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- JPY
- computed
Growth is the furthest below its sector's middle: 0.38 against 0.47 on the market's range.
Follow one yen
lens 1 of 9After what it costs to make
19.5%
After running the business
7.2%
After interest and tax
6.2%
After what it must reinvest
10.9%
Kept after the dividend
8.7%
The five stops
5 of 5 read- After what it costs to make9,897,000,00019.5%
- After running the business3,637,000,0007.2%
- After interest and tax3,161,000,0006.2%
- After what it must reinvest5,528,000,00010.9%
- Kept after the dividend4,409,000,0008.7%
Of every unit of sales, 0.09 is still there after the dividend.
Of every unit of sales, 0.09 is still there after the dividend.
Every figure in this lens
Except where said otherwise: Computed from the filing for 2026
Sales50,650,000,000
- Source
- computed
- Statement
- income
- Fiscal year
- 2026
- Reported in
- JPY
After what it costs to make9,897,000,000
- Source
- computed
- Statement
- income
- Fiscal year
- 2026
- Reported in
- JPY
After running the business3,637,000,000
- Source
- computed
- Statement
- income
- Fiscal year
- 2026
- Reported in
- JPY
After interest and tax3,161,000,000
- Source
- computed
- Statement
- income
- Fiscal year
- 2026
- Reported in
- JPY
After what it must reinvest5,528,000,000
- Source
- computed
- Statement
- income
- Fiscal year
- 2026
- Reported in
- JPY
Kept after the dividend4,409,000,000
- Source
- computed
- Statement
- income
- Fiscal year
- 2026
- Reported in
- JPY